Quantcast

Latest Organofluorides Stories

2014-03-26 16:25:46

- Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months EAST HANOVER, N.J., March 26, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven...

2014-03-25 23:03:54

The Firm is evaluating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statins. New York, New York (PRWEB) March 25, 2014 Hundreds of Lipitor lawsuits (http://www.thelipitorlawsuit.com/) that allege use of the statin drug caused patients to develop new-onset Type 2 diabetes have begun to move forward in a multidistrict litigation underway in U.S. District Court, District of South Carolina. According to an Order...

2014-03-25 23:02:29

Federal litigation involving Pfizer's cholesterol-lowering drug Lipitor has been consolidated before a single judge in South Carolina. (PRWEB) March 25, 2014 The law firm McSweeney / Langevin continues to advise women regarding potential legal claims regarding a possible link between use of Lipitor and the development of type 2 diabetes. Recently, federal litigation involving Pfizer, and plaintiffs alleging Lipitor caused type 2 diabetes, was centralized in South Carolina following...

2014-03-25 08:31:12

MIAMI and NEW YORK, March 25, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,658,663, entitled "Method Of Treating Thermoregulatory Dysfunction With Paroxetine." This method of use patent covers the company's Brisdelle(®) (paroxetine) capsules, 7.5 mg, for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, commonly referred to as hot flashes....

2014-03-24 20:23:39

DUBLIN, March 24, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/zkjlpz/investigation) has announced the addition of the "Investigation Report on China Atorvastatin Market, 2009-2018" [http://www.researchandmarkets.com/research/zkjlpz/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The prevalence rate of abnormal blood lipid in China is lower than that in most developed...

2014-03-24 20:23:34

Five Phase 3 Studies With Evolocumab (AMG 145) to be Featured in Late-Breaking and Clinical Research Presentations - Data Form the Basis of Global Filing Plan THOUSAND OAKS, Calif., March 24, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density...

2014-03-24 16:24:53

TOKYO, March 24, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI(®) capsules 40mg (development code: MDV3100; generic name: enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas filed the application for approval in Japan in May 2013. XTANDI is a once-daily, oral androgen receptor signaling inhibitor that acts on...

2014-03-24 12:31:07

KANSAS CITY, Kan., March 24, 2014 /PRNewswire/ -- Two Kansas women who took Lipitor to reduce their cholesterol levels and later developed diabetes have filed Lipitor lawsuits against Pfizer, announced Robert K. Jenner, attorney with Janet, Jenner & Suggs, LLC. In separate filings, Alice Beems of Topeka (Case no. 2:14-cv-2088), and Nora Hammerschmidt of Plainville (Case no. 2:14-cv-2089) claim Pfizer failed to warn doctors and their patients that Lipitor, also called...

2014-03-21 23:01:52

The Firm is investigating Risperdal lawsuits on behalf of men and boys who allegedly experienced gynecomastia (male breast development) due to Risperdal. New York, NY (PRWEB) March 21, 2014 Johnson & Johnson has been successful in its bid to have a $1.2 billion verdict rendered in an Arkansas Risperdal lawsuit (http://www.risperdallawsuitcenter.com/) overturned, Bernstein Liebhard LLP reports. According to a decision rendered yesterday, the high court ruled that the state had relied...

2014-03-20 23:29:36

National network of attorneys initiates offer of no-cost consultations to consumers seeking compensation for allegations of gynecomastia, other side effects. San Diego, CA (PRWEB) March 20, 2014 http://www.resource4thepeople.com/defectivedrugs/risperdal.html Resource4thePeople announced today that its national network of attorneys is now investigating claims over allegations that the antipsychotic medication Risperdal may cause a breast-growth condition known as gynecomastia or other side...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related